[go: up one dir, main page]

CA2541522A1 - Dosage immunoenzymatique double pour detecter la maladie de l'alzheimer avec applications pour des vaccins therapeutiques visant a enrayer la maladie - Google Patents

Dosage immunoenzymatique double pour detecter la maladie de l'alzheimer avec applications pour des vaccins therapeutiques visant a enrayer la maladie Download PDF

Info

Publication number
CA2541522A1
CA2541522A1 CA 2541522 CA2541522A CA2541522A1 CA 2541522 A1 CA2541522 A1 CA 2541522A1 CA 2541522 CA2541522 CA 2541522 CA 2541522 A CA2541522 A CA 2541522A CA 2541522 A1 CA2541522 A1 CA 2541522A1
Authority
CA
Canada
Prior art keywords
disease
alzheimer
antibody
antigen
alzas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2541522
Other languages
English (en)
Inventor
E. Rick Preddie
Johanna Bergmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 2541522 priority Critical patent/CA2541522A1/fr
Publication of CA2541522A1 publication Critical patent/CA2541522A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2541522 2006-03-28 2006-03-28 Dosage immunoenzymatique double pour detecter la maladie de l'alzheimer avec applications pour des vaccins therapeutiques visant a enrayer la maladie Abandoned CA2541522A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2541522 CA2541522A1 (fr) 2006-03-28 2006-03-28 Dosage immunoenzymatique double pour detecter la maladie de l'alzheimer avec applications pour des vaccins therapeutiques visant a enrayer la maladie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2541522 CA2541522A1 (fr) 2006-03-28 2006-03-28 Dosage immunoenzymatique double pour detecter la maladie de l'alzheimer avec applications pour des vaccins therapeutiques visant a enrayer la maladie

Publications (1)

Publication Number Publication Date
CA2541522A1 true CA2541522A1 (fr) 2007-09-28

Family

ID=38561867

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2541522 Abandoned CA2541522A1 (fr) 2006-03-28 2006-03-28 Dosage immunoenzymatique double pour detecter la maladie de l'alzheimer avec applications pour des vaccins therapeutiques visant a enrayer la maladie

Country Status (1)

Country Link
CA (1) CA2541522A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
CN109073661A (zh) * 2016-05-04 2018-12-21 欧蒙医学诊断技术有限公司 用于神经学疾病的诊断的测定法

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US10538581B2 (en) 2005-11-30 2020-01-21 Abbvie Inc. Anti-Aβ globulomer 4D10 antibodies
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US10323084B2 (en) 2005-11-30 2019-06-18 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN109073661A (zh) * 2016-05-04 2018-12-21 欧蒙医学诊断技术有限公司 用于神经学疾病的诊断的测定法
CN109073661B (zh) * 2016-05-04 2022-12-30 欧蒙医学实验诊断股份公司 用于神经学疾病的诊断的测定法

Similar Documents

Publication Publication Date Title
US11994522B2 (en) Biomarker detection process and assay of neurological condition
Hampel et al. Core biological marker candidates of Alzheimer’s disease–perspectives for diagnosis, prediction of outcome and reflection of biological activity
JP5687332B2 (ja) アルツハイマー病の診断のための処方
Vonder Haar et al. Repetitive closed-head impact model of engineered rotational acceleration (CHIMERA) injury in rats increases impulsivity, decreases dopaminergic innervation in the olfactory tubercle and generates white matter inflammation, tau phosphorylation and degeneration
WO2011160096A2 (fr) Protéine acide fibrillaire gliale, auto-antigènes et auto-anticorps contre ceux-ci en tant que biomarqueurs de lésion neurale ou de trouble ou affection neurologique
JP2021505844A5 (fr)
JP2018510359A (ja) 脳損傷または神経変性を診断するための方法および組成物
US10281477B2 (en) Diagnostic method for parkinson's disease and lewy body dementia
JP2015508887A (ja) Ｃｎｓ損傷についてのバイオマーカーとしての自然免疫タンパク質
US20220057409A1 (en) Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair
US20230349924A1 (en) Determination agent and determination method for tauopathy and dementia-related diseases
CA2541522A1 (fr) Dosage immunoenzymatique double pour detecter la maladie de l'alzheimer avec applications pour des vaccins therapeutiques visant a enrayer la maladie
Yu et al. The electrophysiological and neuropathological profiles of cerebellum in APPswe/PS1ΔE9 mice: a hypothesis on the role of cerebellum in Alzheimer's disease
EP3696192A1 (fr) Cible thérapeutique et anticorps monoclonaux contre elle pour le diagnostic et le traitement de la maladie d'alzheimer
US10295548B2 (en) Ultrasensitive assay for tau and methods of use thereof for assessing traumatic brain injury in tissues and biofluids
US9618522B2 (en) Diagnostic testing in dementia and methods related thereto
US20240264177A1 (en) Biomarker detection process and assay of neurological condition
KR102145438B1 (ko) 퇴행성 뇌질환 발병 위험성 예측용 조성물 및 이를 이용한 퇴행성 뇌질환의 발병 위험성 예측 방법
Contreras Herpes Simplex Virus 1 Infections of the OE Triggers Pathological Processes Characteristic of Early Alzheimer’s Disease
CN121039498A (zh) 神经退行性疾病的体外诊断方法
US11047867B2 (en) Method for determining the risk of developing alzheimer's disease
WO2023049765A2 (fr) Atf3 utilisé en tant que biomarqueur delésion du système nerveux central
KR20200099119A (ko) 퇴행성 뇌질환 발병 위험성 예측용 조성물 및 이를 이용한 퇴행성 뇌질환의 발병 위험성 예측 방법
Wagner et al. Richard Rubenstein, Ph. D., Binggong Chang, MD, Peter Davies, Ph. D. b, Amy K.
Keller Evidence for the unique pathological classification of mutant S0D1-ALS

Legal Events

Date Code Title Description
FZDE Dead